Skip to main content
SpringerLink
Log in

Peginterferon + telbivudine should be avoided at present due to an increased risk of peripheral neuropathy,

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Marcellin P, Avila C, Wursthorn K, Chuang W-L, Lau GK, Peng C-Y, Gane EJ, Fainboim H, Manns MP, Naoumov NV.Telbivudine (Ldt) Plus Peg-interferon (Pegifn) in Hbeag-positive Chronic Hepatitis B - Very Potent Antiviral Efficacy But Risk of Peripheral Neuropathy (Pn). 45th Annual Meeting of the European Association for the Study of the Liver: 14 Apr 2010. Available from: URL: http://www.easl.ch/easl2010

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Peginterferon + telbivudine should be avoided at present due to an increased risk of peripheral neuropathy,. React. Wkly. 1301, 2 (2010). https://doi.org/10.2165/00128415-201013010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201013010-00004

Keywords

Search

Navigation